Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(0.07) per share. This is a 250 percent decrease over losses of $(0.02) per share from the same period last year.
Barclays Maintains Underweight on LTC Properties, Raises Price Target to $35
Barclays analyst Steve Valiquette maintains LTC Properties (NYSE:LTC) with a Underweight and raises the price target from $30 to $35.
